متلازمة العين الجافة بعد أن لا تكفي الدموع الاصطناعية

References

DOI: 10.4140/TCP.n.2016.96

• When a patient continues to have signs and symptoms despite reducing risk factors and adhering to a tears-substitute regimen, an ophthalmologist will add an additional treatment modality, most often an anti-inflammatory agent or a punctal plug, spectacle side shields, or moisture chambers.
• Ophthalmic corticosteroids decrease symptoms and signs of dry eye by decreasing inflammation and may be used on a short-term basis, normally several weeks, for moderate-to-severe dry eye.
• This medication is quite effective in decreasing dry eye signs and symptoms in many patients, with full effect seen after four to eight weeks.
• A 2013 review of published clinical trials comparing cyclosporine with placebo noted that cyclosporine at the approved dosage improved patient symptoms, for example, itching and blurred vision; it also improved the physician's evaluation of treatment response in DED.